nach oben

Erschienen in:

01.04.2006 | Original Paper

COX-2 Polymorphism, Use of Nonsteroidal Anti-Inflammatory Drugs, and Risk of Colon Cancer in African Americans (United States)

verfasst von: Leah B. Sansbury, Robert C. Millikan, Jane C. Schroeder, Kari E. North, Patricia G. Moorman, Temitope O. Keku, Allan Rene’ de Cotret, Jon Player, Robert S. Sandler

Erschienen in: Cancer Causes & Control | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The inducible Cyclooxygenase (COX)-2 enzyme plays an important role in inflammation and carcinogenesis. Recent reports suggest that single nucleotide polymorphisms (SNPs) in the COX-2 gene may alter enzyme function and in turn modify an individual’s risk of colon cancer. We explored the association between the COX-2 Val511Ala SNP and risk of colon cancer among 240 African American cases and 326 African American controls in a population-based, case-control study in North Carolina.

Methods

We used unconditional logistic regression models to determine the odds ratios (ORs) for genotype and risk of colon cancer.

Results

We observed a non-statistically significant inverse association between any Ala COX-2 genotype and risk of colon cancer (OR = 0.62, 95% CI: 0.33, 1.16) among African Americans. The inverse association was present among non-regular NSAID users, use ≤ 3 times/week, (OR = 0.66; 95% CI: 0.32, 1.37) and regular NSAID users, use ≥3 times/week for ≥3 months, (OR = 0.41; 95% CI: 0.11, 1.54).

Conclusions

Our results suggest that the COX-2 Val511Ala SNP does not antagonize the effect of NSAIDs on colon cancer risk and provides support that NSAID use and the COX-2 Val511Ala SNP may contribute to a reduced risk of colon cancer among African Americans.

Collet, JP, Sharpe, C, Belzile, E, Boivin, JF, Hanley, J, Abenhaim, L 1999Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timingBr J Cancer816268CrossRefPubMed

Garcia-Rodriguez, LA, Huerta-Alvarez, C 2001Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugsEpidemiology128893PubMed

Muscat, JE, Stellman, SD, Wynder, EL 1994Nonsteriodal antiinflammatory drugs and colorectal cancerCancer7418471854PubMed

Peleg, II, Lubin, MF, Cotsonis, GA, Clark, WS, Wilcox, CM 1996Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasiaDig Dis Sci4113191326CrossRefPubMed

Suh, O, Mettlin, C, Petrelli, NJ 1993Aspirin use, cancer, and polyps of the large bowelCancer7211711177PubMed

Sturmer, T, Glynn, RJ, Lee, I-M, Manson, JE, Buring, JE, Hennekens, CH 1998Aspirin use and colorectal cancer: post-trial folow-up data from the physicians’ health studyAnn Intern Med128713720PubMed

Smalley, W, Ray, WA, Daugherty, J, Griffen, MR 1999Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based studyArch Intern Med.159161166CrossRefPubMed

La Vecchia, C, Negri, E, Franceschi, S, et al. 1997Aspirin and colorectal cancerBr J Cancer76675677PubMed

Logan, RF, Little, J, Hawtin, PG, Hardcastle, JD 1993Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programmeBMJ307285289PubMed

10.

Giovannucci, E, Rimm, EB, Stampfer, MJ, Colditz, GA, Ascherio, A, Willett, WC 1994Aspirin use and the risk for colorectal cancer and adenoma in male health professionalsAnn Intern Med121241246PubMed

11.

Giovannucci, E, Egan, KM, Hunter, DJ, et al. 1995Aspirin and the risk of colorectal cancer in womenN Engl J Med333609614CrossRefPubMed

12.

Rosenberg, L, Palmer, FR, Zauber, AG, Warshauer, ME, Stolley, PD, Sharpiro, S 1991A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancerJ Natl Cancer Inst83355358PubMed

13.

Rosenberg, L, Louik, C, Shapiro, S 1998Nonsteroidal anti-inflammatory drug use and reduced risk of large bowel carcinomaCancer8223262333CrossRefPubMed

14.

Shaheen, NJ, Straus, WL, Sandler, RS 2002Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugsCancer94950963CrossRefPubMed

15.

Thun, MJ, Henley, SJ, Patrono, C 2002Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issuesJ Natl Cancer Inst94252266PubMed

16.

Thun, MJ, Namboodiri, MM, Calle, EE, Flanders, D, Heath, CW,Jr. 1993Aspirin use and risk of fatal cancerCancer Res5313221327PubMed

17.

Krishnan, K, Ruffin, MT,4th, Brenner, DE 2000Chemoprevention for colorectal cancerCrit Rev Oncol Hematol33199219PubMed

18.

Steele, VE, Hawk, ET, Viner, JL, Lubet, RA 200Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancerMutat Res3137144

19.

Vane, JR, Botting, RM 1998Anti-inflammatory drugs and their mechanism of actionInflamm Res4S78S87

20.

Vane, JR, Bakhle, YS, Botting, RM 1998Cyclooxygenases 1 and 2Annu Rev Pharmacol Toxicol3897120CrossRefPubMed

21.

Williams, CS, Smalley, W, DuBois, RN 1997Aspirin use and potential mechanisms for colorectal cancer preventionThe J Clin Invest10013251329

22.

Vane, JR, Botting, RM 1998Mechanism of action of nonsteroidal anti-inflammatory drugsAm J Med1042S8SCrossRefPubMed

23.

Paik, JH, Ju, JH, Lee, JY, Boudreau, MD, Hwang, DH 2000Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenaseJ Bio Chem2752817328179

24.

Shiff, SJ, Rigas, B 1997Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemoprevention actionsGastroenterology11319921998PubMed

25.

Sano, H, Kawahito, Y, Wilder, RL, et al. 1995Expression of cyclooxygenase-1 and -2 in human colorectal cancerCancer Res5537853789PubMed

26.

Shao, J, Sheng, H, Inoue, H, Morrow, JD, DuBois, RN 2000Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cellsJ Bio Chem2753395133956

27.

Soslow, RA, Dannenberg, AJ, Rush, D, et al. 2000COX-2 is expressed in human pulmonary, colon, and mammary tumorsCancer8926372645CrossRefPubMed

28.

Ristimaki, A, Honkanen, N, Jankala, H, Sipponen, P, Harkonen, M 1997Expression of cyclooxygnease-2 in human gastric carcinomaCancer Res5712761280PubMed

29.

Reedy, BS, Hirose, Y, Lubet, R, et al. 2000Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesisCancer Res60293297

30.

Murata, H, Kawano, S, Tsuji, S, et al. 1999Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinomaJ Bio Chem94451455

31.

Eberhart, CE, Coffey, RJ, Radhika, A, Giardiello, FM, Ferrenbach, S, Dubois, RN 1994Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomasGastroenterology10711831188PubMed

32.

Singer, II, Kawa, DW, Schloemann, S, Tessner, T, Riehl, T, Stenson, WF 1998Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel diseaseGastroenterology115297306CrossRefPubMed

33.

Rhodes, JM, Campbell, BJ 2002Inflammation and colorectal cancer: IBD-associated and sporadic cancer comparedTrends Mol Med81015CrossRefPubMed

34.

Smith, WL, DeWitt, DL 1996Prostaglandin endoperoxide H syntase-1 and 2: the mechanism by which extracellular stimuli activate phospholipases are unresolvedAdv Immunol62167215PubMed

35.

Cox, DG, Pontes, C, Guino, E, et al. 2004Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancerBr J Cancer19339343

36.

Lin, HJ, Lakkides, KM, Keku, T, et al. 2002Prostaglandin H Syntase 2 Variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasiaCancer Epidemiol Biomarkers Prev1113051315PubMed

37.

Frische, E, Baek, SJ, King, LM, Zeldin, DC, Eling, TE, Bell, DA 2001Functional characterization of cyclooxygenase-2 polymorphismsJPET299468476

38.

Hawkey, CJ 1999COX-2 inhibitorsLancet353307314PubMed

39.

Keku, T, Millikan, R, Worley, K, et al. 20025,10-Methylenetetrahydrofolate reductase codon 677 and 1298 polymorphism and colon cancer in african americans and whitesCancer Epidemiol Biomararkers Prev1116111621

40.

Aldrich, TE, Vann, D, Moorman, PG, Newman, B 1995Rapid reporting of cancer incidence in a population-based study of breast cancer: one constructive use of a central cancer registryBreast Cancer Res Treat356164CrossRefPubMed

41.

Ouellet, M, Percival, MD 2001Mechanism of acetaminophen inhibition of cyclooxygenase isoformsArch Biochem Biophys387273280CrossRefPubMed

42.

Kune, GA, Kune, S, Watson, LF 1988Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer StudyCancer Res4843994404PubMed

43.

Sorensen, HT, Friis, S, Norgard, B, et al. 2003Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based studyBr J Cancer8816871692PubMed

44.

Hsieh, CC, Maisonneuve, P, Boyle, P, Macfarlane, GJ, Roberston, C 1991Analysis of quantitative data by quantiles in epidemiologic studies: classification according to cases, noncases, or all subjects?Epidemiology2137140PubMed

45.

Willett, W, Stampfer, MJ 1986Total energy intake: implications for epidemiologic analysisAm J Epidemiol1241727PubMed

46.

Willett, W 1990Nutritional EpidemiologyOxford University PressOxford, United Kingdom

47.

National Heart L, Blood Institute (2004) The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. In: http://www.nhlbi.nih.gov/guidelines/obesity/practgde.htm, ed. Bethesda MD: National Institutes of Health. Washington, DC

48.

Ainsworth BE, Haskell WL, Whitt MC, et al. (2000) Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 32

49.

Richardson, MT, Ainsworth, BE, Jacobs, DR, Leon, AS 2001Validation of the stanford 7-day recall to assess habitual physical activityAnn Epidemiol11145153CrossRefPubMed

Titel: COX-2 Polymorphism, Use of Nonsteroidal Anti-Inflammatory Drugs, and Risk of Colon Cancer in African Americans (United States)
verfasst von: Leah B. Sansbury
Robert C. Millikan
Jane C. Schroeder
Kari E. North
Patricia G. Moorman
Temitope O. Keku
Allan Rene’ de Cotret
Jon Player
Robert S. Sandler
Publikationsdatum: 01.04.2006
Verlag: Kluwer Academic Publishers
Erschienen in: Cancer Causes & Control / Ausgabe 3/2006
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-005-0417-0

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

COX-2 Polymorphism, Use of Nonsteroidal Anti-Inflammatory Drugs, and Risk of Colon Cancer in African Americans (United States)